Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Debunking Myths in the US Healthcare System
Top Ten Searches
gynecomastia empyema henoch–schönlein otitis media dyspnea jaundice ventricle lyme immunodeficiency coolingYour Article Summary
Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone
Journal of Neurosurgery: Pediatrics, 06/05/09
Scott LK et al. – Results of a limited pt series show ziprasidone as safe and effective in pediatric pts with closed head injuries who develop agitation and/or aggression in immediately postinjury. Ziprasidone consistently lowered Riker Sedation-Agitation Scale (SAS) scores in all age groups, with minimal dose adjustments, brief duration of therapy, and no adverse events. A prospective trial of ziprasidone in this population is warranted.
Methods- Report of ziprasidone to treat posttraumatic brain injury (post-TBI) agitation in 20 consecutive pediatric pts
- Secondary aim: to establish an age-specific dosage and identify possible drug side effects
- Case series study of all TBI pts presenting over 18-mo period to pediatric intensive care unit who later developed agitation and/or aggression
- Ziprasidone treatment as sole intervention
- Recording of pre- and post-treatment SAS scores and demographic data
- Children stratified into 4 age groups: < 2 yrs (Group 1), 2–6 yrs (Group 2), 7–12 yrs (Group 3), and ≥ 13 yrs (Group 4)
- Ziprasidone for 20 children with agitation and/or aggression during immediate recovery period from TBI
- Median pt age: 8 yrs (range 9 mo–17 yrs)
- SAS score, before and 24 hrs after ziprasidone initiation, showed significant reduction after initiation
- Initial dose for Groups 1–4: 1.7, 0.9, 0.7, and 0.6 mg/kg, respectively, with final doses of 1.8, 1.5, 1.7, and 0.07 mg/kg, respectively
- Duration of therapy for Groups 1–4: 5, 8, 6, and 3 days, respectively
- Continuous cardiac and blood-pressure monitoring for all pts
- No adverse events in any pt age group
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Diclofenac for acute pain in children
Cochrane Reviews, 10/08/09
Intravenous Sildenafil in the Treatment of Neonates with Persistent Pulmonary Hypertension
The Journal of Pediatrics, 10/19/09
Oral Ibuprofen and Ductus Arteriosus Closure in Full-Term Neonates: A Prospective Case-Control Study
Pediatric Cardiology, 10/30/09
Today in Pediatric Emergencies...keeping you current
Receive free subspecialty "5-minute updates" via email
Diclofenac for acute pain in children
Cochrane Reviews, 10/08/09
Management of acute appendicitis: an imaging strategy in children
Pediatric Surgery International, 10/27/09
Rapid viral diagnosis for acute febrile respiratory illness in children in the Emergency Department
Cochrane Reviews, 10/26/09
Today in Pediatric Neurology...keeping you current
Receive free subspecialty "5-minute updates" via email
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
Risk factors for valproic acid resistance in childhood absence epilepsy
Seizure - European Journal of Epilepsy, 10/21/09
Intellectual Deficits in Children with ADHD Beyond Central Executive and Non-Executive Functions
Archives of Clinical Neurospsychology, 10/16/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


